Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mark Kochenderfer (NPI 1396720454)

Field	Value
Entity Type	Individual
Organization	Mark Kochenderfer
Address	2013 Jefferson St Sw
City	Roanoke
State	VA
ZIP	24014
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 13, 2005

Payer Source	Total Paid
Medicare	$2.5M
Medicaid	$0

Key Findings

MARK KOCHENDERFER is operating as an infusion-focused hematology & oncology physician practice: total Medicare revenue is $2.5M and the top drugs administered are high-cost biologics and immunotherapies, with J9271, J1930, and J9173 appearing as the revenue leaders. The code mix (multiple J-codes for monoclonal antibodies and immunotherapies plus chemotherapy administration CPTs) is typical for an oncology infusion clinic that generates the majority of its revenue from drug administration rather than procedural or facility fees.

Revenue is highly concentrated in a few agents: the top 3 Medicare codes by revenue (J9271, J1930, J9173) account for 61.6% of this provider's total Medicare revenue, with J9271 alone representing $860K (35.5% of total Medicare revenue). This concentration indicates the practice’s financial exposure is tied to a small number of high-cost oncology drugs and their utilization patterns.

Payer mix is effectively single-payer Medicare: the profile shows $2.5M in Medicare revenue and none below for Medicaid, so this provider has no Medicaid billing on file and relies on Medicare for its billed public-payer volume. Analysts should treat Medicaid as absent when modeling reimbursement risk or access for this provider.

Competitive standing on key oncology drugs is generally mid-tier nationally rather than dominant: J9271 ranks #396 of 1841 (78th percentile; typical, unremarkable volume for this code), J1930 ranks #15 of 56 (73th percentile; typical, unremarkable volume for this code), and J9173 ranks #18 of 53 (67th percentile; typical, unremarkable volume for this code). These ranks suggest the provider has respectable, but not market-leading, utilization of these agents compared with national peers.

Evaluation-and-management activity is comparatively strong: 99214 (753 claims, $69.3K revenue, 2.9% of total) ranks #22441 of 479517 (95th percentile; notably above typical national volume) and 99215 (289 claims, $38.7K revenue, 1.6% of total) ranks #6252 of 145531 (96th percentile; notably above typical national volume). This combination of high E/M percentiles with high infusion drug revenue implies a busy outpatient oncology clinic with above-average visit intensity.

The provider appears engaged with enhanced oncology services: M0010 (224 claims, $15.5K revenue, 0.6% of total) ranks #49 of 544 (91th percentile; typical, unremarkable volume for this code), indicating participation in the Enhancing Oncology Model (EOM) payment for monthly enhanced oncology services at rates above many peers. This supports an operational emphasis on care coordination or monthly oncology management payments in addition to drug administration.

In-office ancillary services are notable: lab and specimen codes such as 80053 (1.3K claims, $13.3K revenue) and 85025 (1.6K claims, $12.4K revenue) each rank in the 96th percentile (80053 ranks #1027 of 26416; 85025 ranks #1377 of 32833), and 36415 (916 claims, $7.3K revenue) also ranks in the 96th percentile. These high percentiles for common lab and phlebotomy codes are consistent with a practice that performs substantial on-site monitoring and testing for oncology patients.

There is heterogeneity across secondary drugs and services: some supportive agents and biosimilars show modest-to-low standing (for example, J1568 ranks #325 of 381, 15th percentile; J9217 ranks #3422 of 3683, 6th percentile), while other biologics like J9144 and J9299 sit in lower national percentiles (37th and 32th percentile respectively). This pattern indicates a portfolio dominated by a few high-volume immunotherapies alongside a long tail of less frequently used agents compared with national peers.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

73 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,000	$40	$860K
J1930	Injection, lanreotide, 1 mg	7,200	$40	$316.8K
J9173	Injection, durvalumab, 10 mg	5,100	$60	$316.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,840	$40	$259.9K
J9299	Injection, nivolumab, 1 mg	10,340	$20	$248.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	750	$90	$69.3K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	1,560	$30	$53K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	450	$100	$44.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	290	$130	$38.7K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	1,270	$20	$27.9K

Showing 1–10 of 73

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 73 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Mark Kochenderfer — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

73 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	18	110	12,800	$40	$610.9K
J9299	18	30	12,920	$20	$335.4K
J9144	39	60	8,280	$40	$332.7K
J9173	2	10	5,180	$60	$322.2K
J1930	1	10	3,840	$40	$188.7K
J1568	27	30	1,990	$30	$81.8K
Q5119	27	40	1,570	$20	$39.6K
J0881	27	80	10,200	$1	$34.5K
J2506	28	40	360	$80	$31.2K
J1439	33	50	29,250	$1	$30.5K

Showing 1–10 of 73

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mark Kochenderfer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Amanda Gillespie-twardy	VA	Hematology & Oncology Physician	$1.9M	$0
Joseph Baisden	WV	Radiation Oncology Physician	$1.9M	$0
Joseph Mock	VA	Hematology & Oncology Physician	$1.8M	$0
Kimberly Aderhold	VA	Hematology & Oncology Physician	$1.8M	$0
Suzan Merten	VA	Hematology & Oncology Physician	$1.8M	$90
Padmaja Mallidi	VA	Hematology & Oncology Physician	$1.7M	$0
Donald Vile	VA	Hematology & Oncology Physician	$1.4M	$0
Sheenu Sheela	VA	Hematology & Oncology Physician	$1.3M	$0
Andrew Fintel	VA	Hematology & Oncology Physician	$1.3M	$0
Joshua Morales	VA	Hematology & Oncology Physician	$886.1K	$0

Nearby Providers

Other providers in the same ZIP code as Mark Kochenderfer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Carilion Medical Center	VA	General Acute Care Hospital	$0	$124.7M
Carilion Medical Center	VA	Multi-Specialty Clinic/Center	$0	$73.4M
Carilion Medical Center	VA	Emergency Medicine Physician	$0	$18.1M
Carilion Emergency Services, Inc.	VA	Urgent Care Clinic/Center	$0	$11.1M
Carilion Clinic Patient Transportation, LLC	VA	Air Ambulance	$2.6M	$6.1M
Quest Diagnostics Clinical Laboratories Inc	VA	Clinical Medical Laboratory	$3.9M	$186.2K
Fairlawn Surgery Center, LLC	VA	Ambulatory Surgical Clinic/Center	$997K	$572.4K
Matthew Skelton	VA	Hematology & Oncology Physician	$821.2K	$90
Indy Health Labs LLC	VA	Clinical Laboratory Director (Non-physician)	$563.2K	$236.4K
Ramin Akhavan	VA	Diagnostic Radiology Physician	$707.1K	$2.7K

Mark Kochenderfer — Billing Profile & Reimbursement Data

Sign up for Mark Kochenderfer — Billing Profile & Reimbursement Data policy alerts

Mark Kochenderfer — Billing Profile & Reimbursement Data

Sign up for Mark Kochenderfer — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References